TKI Outcomes in AML Similar Across Racial, Ethnic Groups

Why It Matters

Demonstrating parity in TKI efficacy suggests that removing access barriers could reduce longstanding AML health disparities, guiding clinicians and payers toward more equitable treatment strategies.

Key Takeaways

• TKIs yield similar OS across racial groups in real‑world AML
• Study used Flatiron data from 280 US cancer clinics
• Patients of color younger, more Medicaid, lower socioeconomic status
• 48% Medicare, 52% treated in community cancer centers
• 18% received TKI+HMA; 10% later transplanted

Pulse Analysis

Acute myeloid leukemia remains one of the most lethal hematologic cancers, and targeted therapies such as tyrosine kinase inhibitors have reshaped the treatment landscape. While clinical trials have highlighted the potency of FLT3, IDH1 and IDH2 inhibitors, concerns linger about whether these benefits translate uniformly across diverse patient populations. Historically, Black and Hispanic patients have faced higher rates of complex cytogenetics, lower trial enrollment, and reduced access to stem‑cell transplantation, fueling persistent health‑outcome gaps in AML.

The recent analysis of 482 AML patients drawn from the Flatiron Health Research Database offers a rare real‑world perspective. Spanning 280 U.S. cancer clinics between 2015 and 2023, the cohort included a median age of 69‑70 years, with 70% non‑Hispanic White and the remainder representing Hispanic, Black, Asian and other groups. Approximately half received TKIs as monotherapy while 18% combined them with hypomethylating agents, and 10% proceeded to transplant. Crucially, overall survival and event‑free survival were statistically indistinguishable between patients of color and White patients, despite the former group being younger, more often on Medicaid, and concentrated in lower‑income communities.

These findings carry actionable implications for providers, insurers and policymakers. If equitable distribution of TKIs can neutralize survival disparities, health systems should prioritize removing financial and logistical barriers—particularly in community oncology settings where most patients receive care. Future research must expand beyond FLT3, IDH1/2 inhibitors to newer agents and explore long‑term quality‑of‑life outcomes. By aligning access with efficacy, the oncology field moves closer to a truly inclusive standard of care for AML.